Drug Search Results
More Filters [+]

Betamethasone

Alternative Names: betamethasone, celestone, rinderon, Enstilar, mc2-01, mc2 01, taclonex, Diprosone, Dermoval, dovobet, cal/bdp, Betneval, betesil, BETAMETASONA, betametasone, betamethasonvalerat, betamethasondipropionat, luxiq, sernivo, diprolene, diprolene af, betaderm, betatrex, alphatrex, uticort, valisone, beta-val, dermabet, valnac, betnovate, lotrisone, wynzora, beta 1 kit, bsp 0820, h-paxin
Latest Update: 2024-05-15
Latest Update Note: News Article

Product Description

Betamethasone topical is used to treat the itching, redness, dryness, crusting, scaling, inflammation, and discomfort of various skin conditions, including psoriasis (a skin disease in which red, scaly patches form on some areas of the body) and eczema (a skin disease that causes the skin to be dry and itchy and to sometimes develop red, scaly rashes). Betamethasone is in a class of medications called corticosteroids. It works by activating natural substances in the skin to reduce swelling, redness, and itching.

Mechanisms of Action: GR Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Topical,Intramuscular

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: Psoriasis | Psoriasis | Psoriasis | Tinea | Tinea Pedis | Psoriasis

Known Adverse Events: Folliculitis | Hypopigmentation | Urticaria | Psoriasis | Hypercalcemia | Pain Unspecified | Pruritus | Edema | Headache

Company: LEO Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Betamethasone

Countries in Clinic: Australia, China, India, New Zealand, United States

Active Clinical Trial Count: 13

Highest Development Phases

Phase 3: Candidiasis|Pain Unspecified|Psoriasis

Phase 2: Dry Eye Disease|Dry Eye Syndromes|Keratoconjunctivitis Sicca|Sinusitis

Phase 1: Dermatitis, Atopic|Healthy Volunteers|Oncology Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2021-003790-65

P3

Active, not recruiting

Candidiasis

2024-03-11

2020-004081-19

P3

Active, not recruiting

Psoriasis

2023-12-22

FESS

P2

Recruiting

Sinusitis

2023-12-01

35%

C-200-001

P2

Completed

Dry Eye Disease|Keratoconjunctivitis Sicca|Dry Eye Syndromes

2022-10-12

C-200-001

P2

Completed

Dry Eye Disease|Keratoconjunctivitis Sicca|Dry Eye Syndromes

2022-10-12

Recent News Events